SOPHIA Positions MacroGenics' Margetuximab For Role In HER2-Positive Breast Cancer
MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.
You may also be interested in...
Lackluster Survival Data Likely To Marginalize MacroGenics’ Margenza
While the general lack of an overall survival benefit for MacroGenics’ drug in later-line breast cancer was not surprising, OS data were seen as important for commercial uptake of the drug.
MacroGenics Gets Nod For Margenza In HER2-Positive Breast Cancer
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.
Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.